A Long March After Approval: What You Need To Launch Orphan Drugs In China
Without automatic reimbursement in place, makers of orphan and rare disease drugs must look at innovative alternative ways to make their high-priced new therapies accessible to patients in China.
You may also be interested in...
Agreement between FujiFilm and Hisun sets plan for developing the novel flu drug Avigan in China. Also, CANbridge and WuXi partner in rare diseases, and Kissei gets Asian rights to Rigel’s Tavalisse.
Top corporate executives are increasingly turning their attention to rare diseases in China as changing regulatory policies provide a rare opening, and aided by more physicians advocating for orphan drug access. What does the first ever report on rare diseases in China have to say about the opportunities and challenges?
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.